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Abstract
Background: During informal interviews in the course of an ethnographic study on intergenerational dialogue between
individuals with neurofibromatosis and their parents, many members of Canadian neurofibromatosis associations stated
they continue to be told the condition that afflicts them or their children is the ‘‘elephant man’s’’ disease. Today, even
though well established clinical criteria make it possible to diagnose and differentiate the two diseases, the confusion
between NF1 and the disease of Joseph Merrick, the ‘‘elephant man’’, persists in both media representations and those of
physicians. The objective of this article is to document the persistence of this confusion, to identify the factors that
contribute to it, and to identify its impact on the well being of individuals with NF1.
Methodology: Preliminary stages of an ethnographic study.
Principal Findings: Our findings show that some reference sources, past medical training, and print and online news media
have all contributed to the persistence of the association between NF1 and the disease of Joseph Merrick, the ‘‘elephant
man’’. Our observations suggest that this misconception can have negative medical, social, and psychological impacts on
patients and their families and thus increase the burden of the disease.
Conclusions: Changes of attitude regarding medical teaching and the media could lead to definitively clearing up the
confusion.
Citation: Legendre C-M, Charpentier-Co ˆte ´ C, Drouin R, Bouffard C (2011) Neurofibromatosis Type 1 and the ‘‘Elephant Man’s’’ Disease: The Confusion Persists: An
Ethnographic Study. PLoS ONE 6(2): e16409. doi:10.1371/journal.pone.0016409
Editor: Efthimios Skoulakis, Alexander Flemming Biomedical Sciences Research Center, Greece
Received August 24, 2010; Accepted December 22, 2010; Published February 9, 2011
Copyright:  2011 Legendre et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The work underlying this article was supported by the Association de la Neurofibromatose du Que ´bec (ANFQ) (http://www.anfq.org/), the Foundation
of Stars Children’s Health Research, and the Fonds de Recherche en Sante ´ du Que ´bec (FRSQ) (file number: 16378). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: claire-marie.legendre@usherbrooke.ca
Introduction
During informal interviews in the course of an ethnographic
study on intergenerational dialogue between individuals with
neurofibromatosis and their parents, some members of Canadian
neurofibromatosis associations stated to the authors that they
continue to be told the condition that afflicts them or their children
is the ‘‘elephant man’s’’ disease. This puzzled us, because the
identification of neurofibromatosis with the condition from which
Joseph Merrick, the so called ‘‘elephant man’’, suffered does not
correspond to current medical knowledge.
For many years, it was thought that Joseph Merrick, widely
known as the ‘‘elephant man’’ (Figure 1), suffered from NF1
[1,2,3,4,5,6]. From 1909 on, however, other diagnoses were
advanced. At last, in 1986, Canadian geneticists Tibbles and
Cohen demonstrated that Merrick was actually afflicted with
Proteus syndrome [7].
Today it is known that NF1 is one of the world’s most widespread
mendelian genetic disorders, with a prevalence of 1 in 3,000. In
contrast, Proteus syndrome is a very rare condition, with a prevalence
lower than 1 in 1,000,000 (Table 1 [8,9,10,11,12,13,14]) [15].
Furthermore, diagnostic criteria for both conditions have been well
defined by the NIH (Table 1), and there exist methods of genetic testing
that differentiate reliably between NF1 and Proteus syndrome. In spite
of this, the general public, NF1 sufferers themselves, and some health
professionals continue to be under-informed about NF1 and to confuse
it with Joseph Merrick’s disease [12].
It becomes clear that this is a problematic situation once it is
understood that confusing NF1 with Proteus syndrome and using
the term ‘‘elephant man disease’’ as a name for both can have
serious clinical, social, and psychological repercussions for
individuals with NF1 and their families [1,2,5,16]. As we will
show in this article, despite Tibbles and Cohen’s work and the
further knowledge that has been acquired about the two genetic
disorders since Tibbles and Cohen, the confusion of NF1 with the
disease from which Joseph Merrick suffered continues to be
perpetuated in medical and social representations, by current
linguistic usage, and in some media reports [1,16].
Given current medical knowledge and the psychosocial and
clinical consequences of confusing neurofibromatosis type 1 (NF1)
with the condition suffered by Joseph Merrick, that is, Proteus
syndrome, we wished: 1) to document the persistence and extent of
this fallacy; 2) to identify certain critical factors that contribute to
its persistence; and 3) to evaluate its impact on the health and well
being of individuals with NF1 and their family members. To reach
these objectives, we had to situate our informants’ testimony (and
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exploratory approach, we opted to begin by examining the written
media, because these have a known impact on social representa-
tions, and then follow up by investigating the medical community’s
treatment of the subject, because of the prominent role its
members play in patients’ lives and their influence on the quality
of knowledge transmitted.
In the present article, after presenting a methodological
overview, we examine the persisting confusion between NF1 and
Joseph Merrick’s condition and the forms it takes in the print and
online news media. Thereafter, we provide several examples of the
impact this misconception can have on the health and well being
of individuals with NF1 and their family members. To conclude,
we propose some approaches to reducing the negative impact of
the confusion between NF1 and the ‘‘elephant man’s’’ disease on
the lives of patients and their family members and to ensuring
patients receive better clinical management.
Neurofibromatsis type 1 (NF1)
With a prevalence of 1 in 3,000, NF1 is one of the most
widespread autosomal dominant diseases in the world. One way of
giving an idea of its pervasiveness is to point out that it occurs
almost as often as cystic fibrosis (1 in 3,500) [17]. The disease
predisposes sufferers to a high risk of both benign and malignant
tumours [18]. The diagnostic criteria for NF1 are well known (see
Table 1). Since the NF1 gene is expressed in all of the body’s cells,
its clinical manifestations (Table 1) can be cutaneous, skeletal,
ophthalmological, and neurological [19]. NF1 can give rise to,
among other things, serious esthetic problems (see Figure 2),
learning difficulties, cognitive deficits, and psychosocial problems,
which in turn are frequently associated with academic difficulties
(see Table 1) [20,21,22,23,24].
Proteus syndrome
Unlike NF1, Proteus syndrome is an extremely rare genetic
condition, with only 205 recently published cases worldwide, of
which only 97 satisfy the diagnostic criteria issued by the NIH in
1998 [15]. The causal mutation seems to occur in a consistently
sporadic manner and the subsequent syndrome manifests itself in a
mosaic pattern [15,25]. Contrary to what is the case with NF, no
specific genetic mutation has been identified for Proteus syndrome
[15]. Proteus syndrome manifests as the excessive and unbalanced
growth of multiple tissues and is also characterized by conjunctive
tissue calcifications and narrowing and lengthening of long bones
[15].
Materials and Methods
At the time of writing of this article, we are conducting an
ethnographic study on the state of intergenerational dialogue
between parents and children with neurofibromatosis. The
ethnographic methodological approach entails, among other
things, observing the individuals and groups being studied in the
settings where they interact. In empirical-inductive anthropolog-
ical studies, the environment is not controlled. Thus it is common
for researchers to encounter unforeseen phenomena which,
because of their inherent significance, must be taken into account
regardless of how closely they relate to the set of issues initially
intended to be under study.
This is what occurred during our study on intergenerational
dialogue. In the course of conversations conducted in the field, we
came face to face with a phenomenon that, while it was unrelated
to our research objectives, raised ethical and clinical concerns that
struck us as sufficiently fundamental to form the focus of a
supplementary study. To avoid confusion, we wish to specify here
that it is the results of that supplementary analysis that we are
presenting in this article and not the results of the original study on
ingergenerational dialogue. But since the methodological context
in which we encountered the phenomenon is that of the original
study (which is still under way), we present the approach we took
to methods in chronological order.
Initial methodology
For our study on intergenerational dialogue between parents
and children with neurofibromatosis, our study design comprises
three classical ethnographic investigative methods: 1) critical and
comparative analysis of the literature; 2) participant observation;
and 3) semi-structured interviews [26].
Critical and comparative analysis of the literature. The
purpose of the initial analysis of the literature was to understand
and analyze the medical, psychosocial, and cultural aspects of
neurofibromatosis as discussed to date in the scientific literature. In
standard fashion, this stage occurred prior to that of participant
observation.
Participant observation. Participant observation requires
investigators’ full physical and intellectual immersion in the setting
under study. The participant observation stage of the study on
intergenerational dialogue was begun in 2007. It consisted of: 1)
over 300 hours of in situ observation at events held by NF
Figure 1. A man who suffered from Proteus syndrome (Joseph
Merrick, the ‘‘elephant man’’). Figure 1 is in the public domain in
USA (published before 1923) (see http://fr.wikipedia.org/wiki/Fichier:
Joseph_Carey_Merrick.png).
doi:10.1371/journal.pone.0016409.g001
Neurofibromatosis Type 1 vs Elephant Man’s Disease
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information sessions, directors’ meetings, and so on); 2) a lecture
for the general public on the medical, anthropological, and ethical
aspects of NF; 3) discussions with association members; and 4)
exchanges elicited by our presentations of our research project at
the associations’ annual meetings. By these means, we gathered
important information about NF association members’ experience
of the disease and the difficulties they encounter in daily life. The
observation data and the testimonies gathered from discussions
and numerous informal interviews with association members were
entered in a field journal. Because the interviews were informal
and because they occurred in the context of participant
observation, we did not collect sociodemographic data about our
informants.
Table 1. Comparative table of the two disorders’ various features
*.
NEUROFIBROMATOSIS PROTEUS SYNDROME
Prevalence
Frequent: 1/3,000–1/4,000 live births worldwide Extremely rare: ,1/1,000,000 live births worldwide
Equally prevalent in males and females Two males for every female
Gene
NF1, chromosome 17 (17q11.2) Unknown
Transmission
50% hereditary (autosomal dominant) Sporadic
50% sporadic (de novo mutation) Postzygotic somatic mutation (embryonic lethal in non-mosaic form;
never with diffuse involvement of the entire body)
Diagnostic Criteria
An individual has NF1 if at least two of these criteria are present. An individual has Proteus syndrome if the three general
criteria plus one criterion from category A or two from
category B or three from category C are present.
General Criteria
1. Cafe ´-au-lait spots (at least 6): Diameter .1,5 cm after puberty; .0,5 cm before puberty 1. Mosaic distribution of lesions
2. Neurofibromas (at least 2 of any types) and/or one or more plexiform neurofibromas 2. Sporadic occurrence
3. Axillary and/or inguinal freckling 3. Progressive course
4. Optic gliomas Category A
5. Lisch nodules (2 or more) 1. Cerebriform connective tissue nevus
6. Characteristic osseous lesion (sphenoid dysplasia, thinning of long bone cortex with or
without pseudoarthrosis
Category B (two required)
7. First degree relative with NF1 1. Linear epidermal nevus
2. Asymmetric, disproportionate overgrowth
3. Specific tumors before second decade
Category C (all three required)
1. Lipomas or focal atrophy of adipose tissue
2. Capillary, venous, or lymphatic malformation
3. Facial features including dolichocephaly, a long face, down-slanting
palpebrae, ptosis, depressed nasal bridge, anteverted nares, and open
mouth position while at rest
General clinical manifestations
1. High blood pressure 1. Pulmonary abnormalities
2. Scoliosis 2. Renal abnormalities
3. Malignant tumors 3. Brain malformations
Cognitive and psychological problems
1. Attention deficit (with or without hyperactivity) disorder in 40% to 50% of cases 1. Learning difficulties in 20% of cases
2. Learning difficulties in 30% to 65% of cases 2. Mental retardation in 10% to 15% of cases
3. Slight mental retardation in 1% to 8% of cases (no consensus among authors) 3. Psychological consequences of the disease
4. Difficulty forming friendship in childhood 4. Feeling of isolation
5. Impact on quality of life 5. Social stigmatization
6. Difficulty establishing social relationships 6. Courtesy stigma afflicts family members
7. Psychological/psychiatric disorders
8. Esthetic considerations represent a psychological burden
*Adapted from Cohen, 1993; Hart, 2005; Biesecker, 2006, 2005, 2002; Turner, 2007; NIH, 1998.
doi:10.1371/journal.pone.0016409.t001
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(annual meetings, social activities, daylong information sessions,
directors’ meetings) held by a number of Canadian
neurofibromatosis associations. On average, we met about 40
people at each event. For the most part they were patients and
patients’ family members, but some were health and education
professionals who were well informed about problems associated
with NF1. We were three researchers in the field; and from 2007
on we gathered several hundreds of confidences and stories,
thereby ensuring that data saturation was more than sufficient for
the purposes of a qualitative study.
The emergent phenomenon
S i n c et h ep r e s e n t a t i o n sw em a d er e l a t e dt od i v e r s ea s p e c t so f
NF1, people were inclined to speak to us spontaneously about
what they were experiencing in connection with the disease.
Thus during the participation observation process many NF1
patients or parents of children with NF1 told us of the extent to
which the identification of NF1 with the disease of Joseph
Merrick, the ‘‘elephant man’’, had impacted on their lives both
medically and psychosocially. This phenomenon was not
among the themes we had originally planned to explore.
However, in view of its ethical and clinical significance, this
emergent issue required its own analysis. For this reason, we
undertook an exploratory study aiming to: 1) document the
persistence and extent of this fallacy; 2) identify certain critical
factors that contribute to its persistence; and 3) evaluate its
impact on the health and well being of individuals with NF1
and their family members.
Subsequent critical and comparative analysis of the
literature. In this context we decided to 1) carry out an
analysis of the scientific literature that was tailored to this new issue
about the confusion between Proteus syndrome and NF1; and 2)
pinpoint articles in the print and online news media from 1988 to
2009 in which NF1 was identified with the condition suffered by
Joseph Merrick, the so called ‘‘elephant man’’.
The review of the literature that related specifically to the
phenomenon discussed in the present article was carried out using
databases specialized in medicine (PubMed, MEDLINE, EM-
BASE, Web of Science), psychology (PsycARTICLES, PsycINFO,
ERIC, CAIRN, Academic Search Complete), social sciences
(CBCA Complete, CINAHL, FRANCIS, ProQuest Dissertations
and Theses, Social Work Abstracts, SocINDEX), and philosophy
(Repe `re, Eureka.cc, Philosopher’s Index). We used the following
search terms in both French and English: ‘‘neurofibromatosis type
1’’, ‘‘NF1’’, ‘‘von Recklinghausen disease’’, ‘‘Proteus syndrome’’,
‘‘elephant man’’, ‘‘elephant man disease’’, ‘‘confusion’’, and
‘‘misconception’’.
We looked for articles published from 1909 to the present, since
it was in an article by Parkes Weber published in 1909 that the
premise that Joseph Merrick suffered from NF1 was mentioned for
the first time. Another factor we looked for was the number of
articles published before and after 1986 that maintained the
confusion, since Tibbles and Cohen’s research results clearing up
the confusion were published in 1986.
As for online media articles, we chose 1988 as the starting point
because it is in that year that articles began to appear in the media
pointing out that NF1 does not have anything to do with the
disease Joseph Merrick had. We also took into account certain
print and electronic reference sources available to the general
public in 2008 and 2009.
Subsequent participant observation. Once association
members had told us that they continued to suffer from the
confusion between NF1 and the disease Joseph Merrick had, we
were sensitized to the suffering created by this situation. As of 2008
we began doing poster presentations to explain the difference
between the two diseases at regional, national, and international
scientific events (see Table 2). It was at this time that we also
decided to gather the comments made by physicians and students
who stopped at our poster presentations to discuss how they
themselves or others whom they knew had fallen prey to the
confusion between NF1 and Proteus syndrome.
From that point on, we noted such comments in our field
journals. As was mentioned above in connection with participant
observation, since we were engaging in a process of observation,
we did not collate any sociodemographic data about the people we
spoke with. In any case, these data would not have been useful in
the context of an exploratory study which had as one of its aims to
learn whether the confusion in question persists among physicians
and medical students and if so, why. We were not seeking to learn
the frequency of this phenomenon in the target population. The
kind of study with which such knowledge could be obtained can
only be conducted once the problem has been identified, which is
the scientific purpose served by exploratory studies.
Research subjects. In this context, then, we gathered
comments from 49 subjects (Table 2) who were medical students
or physicians, with ages, specializations, genders, and countries of
origin undifferentiated. The criteria for inclusion were simply that
our informants made comments on the fact that the confusion
persists or that they themselves had been subject to it and their
ideas about the causes of the confusion.
Ethical approval. The Draft 2nd Edition of the Canadian
Tri-Council Policy Statement states: ‘‘Qualitative research approaches
involving a community, group or population of interest (e.g., marginalized or
privileged groups) follows a process of prior dialogue, exchanges and negotiation
of the research, which precedes the formal data collection involving human
participants’’ and ‘‘preliminary activities may include note taking, scribbling,
diary writing, and observation made long before the researcher has any inkling
that these would turn into formal research projects. These types of preliminary
activities are not subject to REB review’’. (Article 10.6, chapter 10, Draft
Figure 2. A woman who suffers from NF1. (Photo: Marie-Soleil
Lemay-Couture.).
doi:10.1371/journal.pone.0016409.g002
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for Research Involving Humans, 2008).
The data presented here emerged from these preliminary
activities: literature review, participant observation, and informal
discussions with members of partner associations. The obtaining of
research ethics board approval is in process for the next stage of
the original study (semi-structured interviews).
Semi-structured interviews: This article will not discuss the
semi-structured interviews, because those relate to the original
study’s theme of intergenerational dialogue. Those interviews will,
however, contain questions about the confusion of NF1 with the
disease of Joseph Merrick, the ‘‘elephant man’’.
Results
Since these empirical data obtained from participant observa-
tion results had raised the ethical question of the confusion
between NF1 and Joseph Merrick’s disease, it became necessary
for us to review and analyze documents on this issue. In what
follows, we present the results of our analysis of scientific articles
and print and online media publications as well as results from
participant observation.
NF1 and Proteus syndrome in the scientific literature
The scientific literature we reviewed and analyzed consisted of
26 articles on NF1 that used the words ‘‘elephant man’’. Of these,
as expected, all those dating form 1909 to 1986 said that Joseph
Merrick suffered from NF1 [27,28,29]. After 1986, some authors
persisted in the confusion. Hostamisligil and Seward actually
question Tibbles and Cohen’s diagnosis [30,31,32]. But for the
most part, the scientific articles published later than 1986 no
longer perpetrate the confusion [1,3,4,16,33], with three of them
explicitly condemning it [1,16,34].
The confusion between NF1 and the ‘‘elephant man’s’’
disease as found in print and online news media
In 1988, two years following the publication of Tibbles and
Cohen’s findings [7], the American newsmagazine Newsweek
reported, in a brief news item called ‘‘What the Elephant Man
really had’’, that Joseph Merrick had not suffered from NF1 [35].
Despite this emergence of the information into the news media,
numerous American newspapers went on associating NF1 with
Joseph Merrick, the ‘‘elephant man’’ [36,37,38,39,40]. In
response, in a letter to the editor that appeared in the New York
Times in 1989, Joan Rudd Engel, a past president of the National
Neurofibromatosis Foundation, explained how distressing this
confusion could be to NF1 patients: ‘‘As brave and inspiring as
[Joseph Merrick] has proved to be, the identification with him for
the many with neurofibromatosis proved frightening and painful
to them and was also inaccurate. It is in the interest of the many,
many thousands of people with neurofibromatosis to see further
comparison with the Elephant Man ended.’’ [41].
A decade later, American anthropologist Joan Ablon was the
first researcher to decry the continued association of NF1 with the
‘‘elephant man’s’’ disease in the media [1]. Nevertheless, the
confusion did not cease. For example, when the first partial face
transplant was performed in France in 2007, French newspapers
[42,43,44] and some American [45] and Canadian [46] media
outlets identified the patient’s disease, which was in reality NF1,
with Joseph Merrick’s condition. Passages in the French media
Table 2. Scientific Events at Which Presentations Were Made on Psychosocial and Ethical Issues Surrounding Neurofibromatosis.
Scientific Event Year Country Context People We Met
Number of People Who
Gave an Opinion
2ie ´me journe ´e scientifique
de l’Axe me `re-enfant (Second
Annual Science Day of the
Mother-Child Center), Centre de
recherche clinique E ´tienne-Le Bel,
CHUS, Sherbrooke, Quebec
2008 Canada A science day at Universite ´
de Sherbrooke
Physicians, medical students 6
6ie `me journe ´e scientifique du
De ´partement de Pe ´diatrie (Sixth
Annual Science Day of the
Department of Pediatrics), CHUS,
Sherbrooke, Quebec
2008 Canada A science day at Universite ´
de Sherbrooke
Physicians, medical students 7
50th Annual Meeting of the Club
de recherches cliniques du Que ´bec
2008 Canada National congress Physicians, medical students 6
58th Annual Meeting of the
American Society of Human Genetics
2008 USA International congress Physicians, medical students 5
51st Annual Meeting of the Club de
recherches cliniques du Que ´bec
2009 Canada National congress Physicians, medical students 5
Les confe ´rences de la Rele `ve
Gilles-Dupuis, Axe me ´re-enfant (Rele `ve
Gilles-Dupuis Speaker Series,
Mother-Child Center), Centre de
recherche clinique E ´tienne-Le Bel,
CHUS, Sherbrooke, Quebec
2010 Canada A science day at Universite ´
de Sherbrooke
Physicians, medical students 15
Assises de ge ´ne ´tique humaine et
me ´dicale (Congress on Human
and Medical Genetics)
2010 France International congress Physicians 5
TOTAL 49
doi:10.1371/journal.pone.0016409.t002
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[an alternate name for NF1], an incurable disease that disfigures
the face, as in the case of the hero of the movie The Elephant Man.’’
[43] The only media outlet to correct the misrepresentation was
ABC News, which later reported that Joseph Merrick had not had
NF1 but Proteus syndrome [47]. Media items discussing that face
transplant since then have continued to identify NF1 with the
‘‘elephant man’s’’ disease [48,49,50,51]. As of 2008, the confusion
between NF1 and Joseph Merrick’s condition could still be found
on Wikipedia, and as of July 2009 the Dictionary.com entry for the
term ‘‘elephant man’s disease’’ stated that it is NF1 and that it is so
called because Joseph Merrick suffered from it [52].
The confusion between NF1 and Joseph Merrick’s
disease in the medical world
Even though the clinical differences between NF1 and Proteus
syndrome are known, and despite the diagnostic methods available
nowadays, the confusion persists not just in press representations
but also in those of physicians. A few of our informants’ stories of
their experiences will suffice to illustrate this. For instance:
‘‘During dinner with friends, the conversation came around to
the fact that my nephew had just been diagnosed with NF. A
doctor who was present told me it was what the ‘‘elephant man’’
had had’’ (E ´rika, aunt of a child with NF1, Field Notes, 2008). (In
order not to weigh down the text, we only quote one interview
excerpt for each of the points raised by the study subjects. But the
excerpts have been chosen with a view to reflecting the perspective
of the largest possible number of people.) A comment of this kind
provokes great anxiety and raises many questions: In this
informant’s place, one might wonder, ‘‘Do his parents know?
Should I tell them – and what can I tell them? Will my nephew be
able to go to school and take part in sports? What will he look
like?’’ In confirmation of this, an informant who is a physician well
informed about the difference between the two diseases expressed
dismay at the fact that ‘‘so much ignorance exists around the
subject of NF1’’ (Paul, physician, Field Notes, 2008).
In a clinical context, given the hierarchical relationship between
physicians and patients, the association between NF1 and Proteus
syndrome can have important psychological and medical reper-
cussions. One patient told us the following in explaining that she
was told more than once that she has the ‘‘elephant man’s’’
disease: ‘‘The first time was when I was 15. The first neurologist
who followed me told me I had the ‘elephant man’s’ disease. Even
the family physician who followed me between ages 15 to 25 often
said to me, ‘Don’t forget you have the ‘elephant man’s’ disease,
you could end up looking like him’. I didn’t find this funny. The
only thing he knew about the disease was what you could find in
outdated medical encyclopedias. I don’t resent him for this,
though. It’s thanks to him that I was diagnosed’’ (Kathy, woman
with NF1, Field Notes, 2009). Another informant told us,
‘‘Hearing a doctor tell you in the ER (Emergency Room) that
your child has the ‘elephant man’s’ disease is traumatic’’ (Joyce,
mother of a child with NF, Field Notes, 2008).
It is usually from their associations or from specialists familiar
with NF1 that patients learn they don’t have the condition from
which Joseph Merrick suffered. Sometimes patients or family
members have to inform physicians of this: ‘‘I actually had to
explain to [the doctor] the difference between NF1 and Proteus
syndrome. That was so very frustrating to hear that from a doctor
in 2008’’ (Joyce, woman with NF1, Field Notes, 2009). Testimony
to this effect from our informants confirms what Radtke et al.
wrote in 2006: ‘‘Many families continue to be misinformed that
NF1 is the ‘Elephant Man Disease’.’’ [16].
Since many physicians currently practicing were trained before
the publication of Tibbles and Cohen’s article in 1986, we can
expect the confusion between NF1 and Proteus syndrome to
continue for some years. During our poster presentations, many
physicians we spoke to made comments like that of Georges:
‘‘When I was a resident, we were taught that Joseph Merrick
suffered from NF1’’ (Georges, MD, PhD, Field Notes, 2008).
Medical students also often made comments about NF1 like this
one: ‘‘Hey, I know about that disease! It’s the disease the ‘elephant
man’ had; we talked about it in class’’ (Joan, medical student, Field
Notes, 2009). Finally, Stedman’s Medical Dictionary provides two
definitions of ‘‘elephant man’s disease’’, one being that it is a
synonym for Proteus syndrome and the other that it is a colloquial
way of referring to NF1 [53].
A final point is that some physicians actually view the confusion
as yielding benefits in the form of publicity for NF1: ‘‘If it brings
NF1 to the attention of people around the world and makes it clear
that it’s a serious disease, that’s a good thing’’ (John, MD, PhD,
Field Notes, 2008). People who live with NF1 do not take this
view. ‘‘We’ve been fighting for years to put an end to this
confusion…. All it does is reinforce prejudices about the disease
and intensify the sufferings of patients and their family members’’
(Gloria, mother of a child with NF1, Field Notes, 2007).
The impact of the confusion between NF1 and Proteus
syndrome on the health and well being of individuals
with NF1 and their family members
As we have seen, some reference sources, past medical training,
and the print and online news media have all contributed to the
persistence of the association between NF1 and the disease of
Joseph Merrick in representations by the general public and health
professionals. The viewpoint of patients and their family members
is that this confusion distorts how people perceive individuals with
NF1. Moreover, it is known that NF1 sufferers experience
difficulty establishing social ties and developing good self-esteem
[54,55]: having their condition identified as the same disease as the
‘‘elephant man’’ had or given the name ‘‘elephant man disease’’
can only deepen this difficulty.
A press release published in 2001 by the board of directors of
Quebec’s neurofibromatosis association provides a good overview
of the impact of this confusion on patients and their families: ‘‘The
Board of Directors of the Association de la neurofibromatose du
Que ´bec (ANFQ) is concerned about the fact that a few members
of the medical profession continue to associate neurofibromatosis
with elephant man disease…. The stakes of this identification are
considerable: considering the imaginary stigma created by the
publicity given to the elephant man, it is a tragic event in a family
to learn that one or more of its members, with neurofibromatosis,
allegedly suffer from elephant man disease, that is, that their condition
could degenerate to the point of being a monster. As a result,
people with the disease and their close ones can become
profoundly affected by the idea of such an eventuality.’’ [5]
(Provided in English on the Association’s web site; italics in the
original.)
For those with NF1, believing they have Joseph Merrick’s
condition or knowing others believe this heavily compromises their
hopes of a normal social life, employment that interests them, an
enduring couple relationship, and raising children [56,57]. When
they learn that 50% of NF1 cases are inherited and that the
condition is genetically dominant, they are likely, if they believe
the condition they are at risk of transmitting is Joseph Merrick’s
condition, to dread that their children will look like the ‘‘elephant
man’’. A misunderstanding of this kind influences the process of
arriving at decisions about having offspring: ‘‘When I was
Neurofibromatosis Type 1 vs Elephant Man’s Disease
PLoS ONE | www.plosone.org 6 February 2011 | Volume 6 | Issue 2 | e16409diagnosed, the physician told my husband and me that it would be
best if I had my tubes tied, because all our children would have the
disease. That’s what I did, and I was stunned to learn later that
what he had said wasn’t true. First of all, the disease isn’t that bad;
and there were other solutions’’ (Be ´atrice, woman with NF1, Field
Notes, 2007).
Furthermore, even though NF1’s prevalence is similar to that of
cystic fibrosis, one of the main problems faced by individuals with
NF1 is to find a physician who can provide clinical management
during their adulthood (all of the affected persons we have met
mentioned this problem). NF1 sufferers often require referrals to
specialists of several different kinds (geneticist, dermatologist,
neurologist, psychologist and ophthalmologist), so their family
physician must be well informed about their disease. And finally,
the prospect of becoming like the ‘‘elephant man’’ needlessly
complicates clinical management and does harm to the mental
health of NF1 patients. We now know that the disease’s visibility
can have an impact on the quality of life of NF1 sufferers [58] and
that there is a significant association between the disease’s visibility
and psychiatric morbidity [57,59].
Discussion
We have seen that, despite the demonstrable damaging effects
of the failure to differentiate between NF1 and Joseph Merrick’s
condition, despite the known major differences between the two
conditions, and despite the diagnostic methods available today, the
confusion between NF1 and Proteus syndrome persists. Testimo-
nies from the members of Canadian neurofibromatosis associa-
tions and our findings from a literature review and field
observations suggest that two factors chiefly contribute to this
situation: 1) many news medias’ failure to reflect more accurate
recent knowledge about the ‘‘elephant man’s’’ real condition; and
2) the association between NF1 and the ‘‘elephant man’s’’ disease
made by numerous physicians.
In connection with both factors, our data suggest that
continuing to misleadingly use the term ‘‘elephant man disease’’
as a name for NF1 or to erroneously identify NF1 with Joseph
Merrick’s condition contributes to a climate of inadequate
knowledge about the condition, and this can only harm the health
and quality of life of patients and their family members. Thus the
whole issue raises major professional-ethics, bioethical, and
socioethical questions.
From the point of view of professional ethics, physicians have
the duty to consider their own capabilities and limitations in
exercising their profession. This means referring patients with
suspected NF1 to colleagues with appropriate expertise or to
specialized NF clinics. In patients’ best interests, physicians must
refrain from giving information about a disease about which they
have little knowledge.
Speaking bioethically, if the medical community were better
informed about NF1, the feelings of dread experienced by patients
and their families would be reduced. Patients would also receive
better clinical management of their cases. To strive for these
improvements corresponds to the bioethical principle of benefi-
cence: 1) do no harm, 2) maximize possible benefits, and 3)
minimize possible harms. For the sake of patients and their
families, it is essential to work towards definitively clearing up the
confusion.
Socioethically speaking, confusing NF1 with Proteus syndrome
or using the same term, elephant man disease, to designate both
affects patients’ self-perception and their hopes for a job, a family,
and a normal social life. The confusion further stigmatizes them
and adds to the disease’s own difficulties (Table 1). As well, there
are approaches to teaching-and-learning especially suited to
helping children with NF1 that can be adopted in school settings
[60,61]. If a lack of awareness about NF1 results in children being
deprived of these approaches, they could needlessly suffer major
negative impacts on their cognitive and psychosocial development.
Conclusion
Given the nature of the problems we have just discussed, it
could take no more than a few changes of attitude by the medical
and scientific communities to make significant improvements.
Physicians and scientists could send letters with corrective
information to those media, publishers, and web sites that
associate NF1 with the ‘‘elephant man’’ or refer to it as elephant
man disease. It is noteworthy that we found no instances of the
confusion between NF1 and Joseph Merrick’s disease in the New
York Times subsequent to the appearance of the letter from the
National Neufibromatosis Foundation’s past president [41].
NF1 specialists in various fields could take a more direct part in
knowledge transfer and physicians’ continuing education. Thus
family physicians and pediatricians who have little familiarity with
NF1 would learn that they can refer their patients with NF1 to NF
clinics [2,16,60] and such specialists as geneticists, neurologists,
and dermatologists. Patients and their family members would
benefit from better tailored clinical management of their cases,
perhaps even optimal management. This would include having
access to better information [16,19], appropriate genetic counsel-
ing [62], and psychological support from an early age [63], as well
as receiving follow-up for learning disorders specific to NF [12,64].
The literature shows that NF1 sufferers who are referred to
specialists able to treat their physiological, psychosocial, and
cognitive problems can look forward to significant improvements
in their health, quality of life, and ability to integrate socially
[12,60].
On a different note, in the school setting, it is important for
teachers to be informed that the main difficulties faced by children
with NF1 are not related to intelligence but to learning problems
and attention disorders [20,65]: teachers could learn of the various
teaching-and-learning approaches that exist to palliate these
children’s and teenagers’ learning challenges and psychosocial
fragility [57].
Finally, we hope this article will contribute in some small degree
to showing the importance of the roles of the media and physicians
in transferring knowledge about NF1 and thus in improving the
conditions of life and health of people with NF1 and their families.
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